Document is current

Article History

Received: 24 September 2023

Accepted: 11 April 2024

First Online: 19 April 2024

Declarations

:

: The study (Protocol version 2.0, October 8, 2022) was approved by the Ethics Committee of the Cancer Hospital&Shenzhen Hospital Chinese Academy of Medical Sciences (YW2022-21–3) and the Cancer Hospital Chinese Academy of Medical Sciences (23/283–4025). It was registered at Clinicaltrials.gov (NCT05794750) with the name “Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC (AK104-IIT-13)”. The study protocol had been approved by all participant centers. The principal investigator was responsible for submitting the protocol amendments and changes to the informed consent document to the Institutional Review Board(s) and/or Independent Ethics Committee(s) at each center and obtaining their approval where necessary. If substantial amendments to the protocol and other relevant study documents were required, the principal investigator would ensure that they were implemented only after approval by the relevant regulatory authorities. The Human Ethics Committee of the Cancer Hospital and Shenzhen Hospital Chinese Academy of Medical Sciences and the Cancer Hospital Chinese Academy of Medical Sciences had granted central ethical approval. All personnel involved in conducting the current study should abide by the latest Declaration of Helsinki and Ethical Guidelines for Clinical Studies. Written informed consent would be obtained from all participants.

: Not applicable.

: The authors declare no competing interests.